Please use this identifier to cite or link to this item:
|Title:||The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.|
Van Pesch, Vincent
Saladino, Maria Laura
Amato, Maria Pia
MSBase study group
|Keywords:||MSBase;Multiple sclerosis;disease-modifying therapy;fingolimod;medication persistence|
Multiple Sclerosis, Relapsing-Remitting
Proportional Hazards Models
|Abstract:||We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p Following the availability of fingolimod, patients were more likely to discontinue injectable treatments. Those who switched to fingolimod were more likely to do so for convenience. Persistence was improved on fingolimod compared to other medications.|
|Appears in Collections:||Producción 2020|
Files in This Item:
There are no files associated with this item.
This item is protected by original copyright
Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.